Ipsen’s partner, Lexicon, announced FDA Priority Review of new drug application for telotristat etiprate for the treatment of carcinoid syndrome

 

Sans-titre-1

 

 Lexicon Announces FDA Priority Review of New Drug Application for Telotristat Etiprate for the Treatment of Carcinoid Syndrome

 

May 31, 2016

 

Read the press release >

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019